significance were noted.
-- Part 2 is a multiple ascending dose study of R7128 conducted in 40
patients chronically infected with HCV genotype 1 who have previously
failed interferon therapy. The primary objective of Part 2 is to
assess the safety, tolerability and pharmacokinetics of R7128 after
once-daily or twice-daily dosing for 14 days. The secondary objective
is to assess antiviral efficacy by measuring the change in HCV RNA.
About Hepatitis C
Hepatitis C is a blood-borne infectious disease of the liver and is a leading cause of chronic liver disease and liver transplants. The WHO estimates that nearly 180 million people worldwide, or approximately 3% of the world's population, are infected with hepatitis C virus (HCV). The CDC has reported that almost four million people in the United States have been infected with HCV, of whom 2.7 million are chronically infected.
Alan Roemer, Vice President
Investor Relations & Corporate Communications
Office: (609) 613-4125
Pharmasset "Safe Harbor" Statement under the Private Securities
Litigation Reform Act of 1995: Statements in this press release regarding
our business that are not historical facts are "forward-looking statements"
that involve risks and uncertainties, including without limitation the risk
that there will be a delay in the presentation of R7128 data at upcoming
conferences, the risk that the R7128 data to be presented at upcoming
conferences is not accurate or representative, the risk that the
preliminary data from the R7128 Phase 1 Study is not accurate or
representative, the risk that our collaboration with Roche will not
continue or will not be successful, the risk that the on-going or
anticipated clinical trials for any one or more o
|SOURCE Pharmasset, Inc.|
Copyright©2007 PR Newswire.
All rights reserved